{"id":"W3178692749","doi":"10.1016/j.euo.2021.05.007","title":"Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Axitinib; Pembrolizumab; Discontinuation; Sunitinib; Adverse effect; Internal medicine; Renal cell carcinoma; Gastroenterology; Incidence (geometry); Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002674599,0.0003021545,0.0006538478,0.00009137984,0.00009409739,0.000007799013,0.0001179147,0.00009843406,0.00005964775],"category_scores_gemma":[0.00008073526,0.0002099578,0.00008277511,0.0002151062,0.0001505266,0.00004917003,0.0001571277,0.0002027904,0.0000123972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000461611,"about_ca_system_score_gemma":0.0001628282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008985626,"about_ca_topic_score_gemma":0.0003171065,"domain_scores_codex":[0.9970555,0.0009552304,0.0007662267,0.0006766949,0.0001936375,0.0003527438],"domain_scores_gemma":[0.9984312,0.0003370168,0.000432976,0.0005633355,0.0001179373,0.0001175305],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5587467,0.007264902,0.3207658,0.0002401994,0.0009964532,0.00684788,0.006231367,0.00102852,0.01107692,0.00003895257,0.0001105598,0.08665179],"study_design_scores_gemma":[0.1493699,0.01698579,0.8283333,0.0000491817,0.0004762004,0.00002320809,0.00008422914,0.0001477248,0.002308353,0.000003397161,0.002072634,0.000146101],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938879,0.0002294925,0.00008211104,0.001152447,0.0002513481,0.001446519,0.000111907,0.00002451334,0.002813783],"genre_scores_gemma":[0.9967519,0.0005329733,0.0005030308,0.0003026666,0.0001301973,0.00005227234,0.001347343,0.00004539231,0.0003341924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5075675,"threshold_uncertainty_score":0.8561829,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02050670095494227,"score_gpt":0.2432564093743557,"score_spread":0.2227497084194134,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}